CRISM Therapeutics:
specialises in creating better treatments that deliver already approved drugs directly to sites in the body where they are needed and will be most effective.
Our unique platform uses modified hot-melt extrusion techniques to incorporate drugs into biodegradable and biocompatible polymers such as PLGA (polylactic-co-glycolic acid copolymer) and EVA (ethylene vinyl acetate).
By developing drug delivery techniques that mix drugs with polymers and assessing their efficacy, drugs that are poorly soluble or large complex molecules can be developed to their full potential.
Our interdisciplinary team of experts consults on all aspects of drug formulation and development, covering the whole pipeline. Our rapid formulation development and screening processes, coupled with our expertise in scale-up and regulatory requirements, make progress to clinical trials and registration easier, quicker and more cost-effective.
Our extensive resources, available for the creation and development of new formulations, include:
A range of mixers and extruders, including the smallest commercially available twin-screw extruder in the UK
Full analytical suite including rheology, differential scanning calorimetry (DSC), dissolution, high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC/MS), X-ray diffraction, Raman mapping and stability testing
Filament- and pellet-fed fused deposition modelling 3D printers for the development of personalised treatments
Full tabletting suite
Preclinical models for a range of solid tumours, pharmacokinetics and pharmacodynamics, and Good Laboratory Practices toxicity testing